Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.48 |
| ▸ | PRNP | P04156 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | AHR | P35869 | 2/20 | 0.44 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.44 |
| ▸ | VDR | P11473 | 1/20 | 0.44 |
| ▸ | PTGFR | P43088 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6170956 | 0.89 | L3MBTL1 (0.47) | MAPTSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL6170480 | 0.89 | LTB4R (0.45) | MAPTSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL14570639 | 0.88 | PRNP (0.57) | MAPTKMT2AMEN1L3MBTL1LTB4R | |
| SCHEMBL25224251 | 0.87 | L3MBTL1 (0.43) | MAPTSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL30533423 | 0.87 | L3MBTL1 (0.43) | MAPTSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL30533422 | 0.87 | L3MBTL1 (0.43) | MAPTSMN1; SMN2KMT2AMEN1L3MBTL1 | |
| SCHEMBL26565172 | 0.87 | L3MBTL1 (0.49) | MAPTKMT2AMEN1L3MBTL1PRNP | |
| SCHEMBL1757872 | 0.86 | MEN1 (0.49) | MAPTKMT2AMEN1L3MBTL1LTB4R | |
| SCHEMBL6172146 | 0.86 | L3MBTL1 (0.51) | MAPTKMT2AMEN1L3MBTL1LTB4R | |
| SCHEMBL31253421 | 0.86 | MAPT (0.49) | MAPTSMN1; SMN2KMT2AMEN1LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150973-B1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6710209-B2 | INHIBITING FARNESYL PROTEIN TRANSFERASE. | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | MAPT 4805/4885SMN1; SMN2 3289/4885KMT2A 1850/4885 |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | MAPT 4805/4885SMN1; SMN2 3289/4885KMT2A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.